Search Results
Your search for ,had matches 18609 pages
Showing 17851 - 17900Study Identifies Frequent Cause of Breast Cancer Resistance to Investigational PI3K-Alpha Inhibitor
Loss of the tumor suppressor PTEN was a frequent cause of resistance to the investigational drug BYL719, which blocks the activity of the PI3K-alpha protein, in a small sample of women with breast cancer that progressed after initially responding to BYL719 treatment, according to results presented...
Crossover Trial Indicates Preference for Pazopanib Over Sunitinib in Patients With Metastatic Renal Cell Carcinoma
A crossover trial reported in the Journal of Clinical Oncology by Escudier et al found that patients with metastatic renal cell carcinoma preferred pazopanib (Votrient) vs sunitinib (Sutent) treatment. Study Details In the double-blind study, 168 patients with no prior systemic therapy for...
Six Months Hormonal Treatment in Addition to Radiotherapy Improves Survival for Men With Localized Prostate Cancer
Men with localized prostate cancer that is at risk of growing and spreading have a lower risk of disease progression and recurrence if they are treated with radiotherapy combined with androgen-deprivation therapy, according to new research. The findings, which were presented at the 33rd Conference...
Preclinical Study Identifies Potential New Approach to Overcome Breast Cancer Resistance to HER2-Targeted Therapies
Resistance to a combination of HER2-targeted therapies, trastuzumab (Herceptin) and lapatinib (Tykerb), was associated with elevated activation of a group of proteins called fibroblast growth factor receptors (FGFRs), which are the target of a number of drugs currently being developed, according to ...
Study Identifies Potential Predictor of Clinical Outcome in Patients With Lung Cancer Treated With MK-3475
Among patients with non–small cell lung cancer (NSCLC) treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes, according to results of a phase I clinical trial presented at the American...
Investigational Bromodomain Inhibitor Shows Clinical Activity in Some Blood Cancers
The results from a phase I study of a new investigational epigenetic therapy called OTX015, a small-molecule inhibitor that blocks the activity of bromodomain and extraterminal (BET)-bromodomain proteins, is showing clinical activity in some blood cancers, including leukemia and lymphoma. The study ...
Prognosis of HPV-Positive Head and Neck Cancer Varies According to Tumor Site
Patients with cancer of the throat and who are positive for the human papillomavirus (HPV) have a good prognosis, but until now the effect of being HPV-positive on the prognosis of tumors located elsewhere in the head and neck was unknown. A new study presented at the 33rd Conference of the...
Phase I Trial of New Antibody-Drug Conjugate Shows Promise Against All Forms of Melanoma
A small clinical study of a new investigational antibody-drug conjugate called DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or ocular melanoma has found the drug to be safe and tolerable and demonstrated early evidence of antitumor activity. The findings were presented...
New Test Developed to Detect Men at High Risk of Prostate Cancer Recurrence
A new genetic signature to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, according to a study presented at the 33rd Conference of the European Society for Radiotherapy and Oncology in...
I-SPY 2 Results Identify Subset of Breast Cancer Patients Most Likely to Benefit From Neratinib
Findings from the I-SPY 2 randomized phase II clinical trial for women with newly diagnosed stage II breast cancer show that a neoadjuvant regimen containing the investigational drug neratinib, a pan-HER inhibitor, and standard chemotherapy is beneficial for patients with hormone...
Investigational Drug Demonstrates Early Promise in Metastatic Breast Cancer
The novel oral drug LY2835219, an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, showed early promise as monotherapy for patients with metastatic breast cancer, particularly for those with hormone receptor–positive disease, according to results of a phase I study presented at the...
Biomarker Identifies Melanoma Patients Who May Respond to Immunotherapy MK-3475
Among melanoma patients treated with the PD-1 inhibitor MK-3475, those whose tumors had the protein PD-L1 had better immune responses and higher survival rates, according to results presented at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego. When the protein...
Certain Genetic Variants May Help Identify Patients at Increased Risk of Bladder Cancer Recurrence
A new study by Andrew et al published in BJU International suggests that certain inherited DNA sequences may affect the prognosis of patients with bladder cancer. The findings may help physicians identify subgroups of patients with high-risk bladder cancer who should receive more frequent...
Validation of Mantle Cell Lymphoma International Prognostic Index in European Mantle Cell Lymphoma Network Trials
The Mantle Cell Lymphoma International Prognostic Index (MIPI) was developed in 2008 as the first prognostic stratification system specific for mantle cell lymphoma (MCL). In a study reported in the Journal of Clinical Oncology, Hoster et al confirmed the validity of MIPI in a cohort of two...
HLA Class I Antigen Expression Predicts Overall Survival Benefit With Aspirin Use in Colon Cancer
In a cohort study reported in JAMA Internal Medicine, Reimers et al found that aspirin use was associated with a significant 47% reduction in mortality risk after diagnosis of colon cancer expressing HLA class I antigen. There was no difference in aspirin benefit according to strong or weak...
Dose-Escalated Hypofractionated IMRT for Localized Prostate Cancer Has Similar Side Effects Compared to Conventional IMRT
Dose-escalated intensity-modulated radiotherapy with use of a moderate hypofractionation regimen (72 Gy in 2.4-Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late toxicity, according to a study by Hoffman et al published in the International Journal ...
Findings of AURELIA Trial Support Consideration of Bevacizumab/Chemotherapy in Carefully Selected Patients With Platinum-Resistant Ovarian Cancer
The recently reported open-label phase III AURELIA trial showed that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvements in progression-free survival, the primary study endpoint, and objective response rate in women with recurrent platinum-resistant ovarian...
Addition of Bevacizumab to Chemotherapy Improves Patient-Reported Outcomes in Platinum-Resistant Ovarian Cancer
The recently reported open-label phase III AURELIA trial showed that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvement in progression-free survival, the primary study endpoint, and objective response rate in women with recurrent platinum-resistant ovarian...
Long-Term Study Finds Fertility Drugs Do Not Increase Breast Cancer Risk
A large study of over 12,000 women who took clomiphene citrate or gonadotropins for the treatment of infertility has found no increase in breast cancer risk over 30 years of follow-up, compared with women who were not treated with these medications. The study by Brinton et al is published in Cancer ...
Adding Bevacizumab to Chemotherapy Improves Progression-Free Survival in Platinum-Resistant Recurrent Ovarian Cancer
Single-agent chemotherapy is standard in platinum-resistant ovarian cancer. In the open-label phase III AURELIA trial reported in the Journal of Clinical Oncology, Pujade-Lauraine et al found that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvement in...
Study Finds Routine Mammograms Offer Limited Benefit to Oldest Female Patients
Doctors should focus on life expectancy when deciding whether to order mammograms for their oldest female patients, since the harms of screening likely outweigh the benefits unless women are expected to live at least another decade, according to a review published online in JAMA by Walter and...
18F-FDOPA PET Predicts Good Prognosis as Soon as 2 Weeks After Start of Antiangiogenic Therapy in Recurrent High-Grade Glioma
In a study reported in Clinical Cancer Research, Schwarzenberg et al found 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-FDOPA) positron-emission tomography (PET) metabolic tumor volume values at 2 weeks after the start of bevacizumab (Avastin) were highly predictive of outcome in patients with ...
Bendamustine/Rituximab May Be Important Alternative Treatment Option for Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Results from the BRIGHT study combined with long-term safety data from other studies suggest that bendamustine (Treanda) plus rituximab (Rituxan) “may be an important alternative treatment option” for the initial therapy of patients with low-grade non-Hodgkin lymphoma (NHL) and mantle...
Patient Characteristics and Outcome Differ in Clinical Trial vs General Population Elderly Patients With Hormone Receptor–Positive Breast Cancer
In a study reported in the Journal of the National Cancer Institute, van de Water et al found that Dutch women with hormone receptor–positive breast cancer aged ≥ 65 years at diagnosis who were treated in a clinical trial had significantly fewer comorbid diseases, higher socioeconomic...
Radiofrequency Ablation Reduces Risk of High-Grade Dysplasia and Adenocarcinoma vs Endoscopic Surveillance in Patients With Barrett’s Esophagus
Barrett’s esophagus with low-grade dysplasia increases risk of esophageal adenocarcinoma. In a European study reported in JAMA, Phoa et al assessed whether endoscopic radiofrequency ablation reduced the rate of neoplastic progression compared with endoscopic surveillance in patients with...
Study Finds Chemotherapy Accelerates Molecular Aging in Patients With Breast Cancer
Physicians have long suspected that chemotherapy can accelerate the aging process in patients treated for cancer. Using a test developed at UNC Lineberger Comprehensive Cancer Center to determine molecular aging, oncologists have directly measured the impact of anticancer chemotherapy drugs on...
Women Are Infrequently First or Corresponding Authors in Collaborative Group Publications in Oncology
As reported in a research letter in JAMA Internal Medicine, Sun et al studied the frequency with which women lead clinical trial publications from organized collaborative groups in oncology. They found that women are very infrequently lead or corresponding authors, with the percentages not changing ...
DNA Test Can Help Predict Bladder Cancer Recurrence
A DNA methylation marker test performed on patients with noninvasive urothelial carcinoma can predict tumor recurrence with high sensitivity and specificity, according to a study by Su et al. The findings may help eliminate costly and unnecessary invasive exams and reveals the importance of DNA...
Anastrozole Reduces Breast Cancer Incidence in High-Risk Postmenopausal Women
In the phase III IBIS-II trial, reported in The Lancet, Cuzick et al found that aromatase inhibitor therapy with anastrozole reduced risk of breast cancer in postmenopausal women at high risk of the disease. Study Details In this double-blind trial, 3,864 postmenopausal women aged 40 to 70 years...
FDA Panel Endorses Stool-Based DNA Colon Cancer Test
The U.S. Food and Drug Administration’s (FDA) committee of genetic experts has determined that Cologuard, a stool-based DNA, noninvasive screening test for colorectal cancer, has demonstrated safety, effectiveness, and a favorable risk-benefit profile. The FDA is now considering the...
Ceritinib Highly Active in Patients With ALK-Rearranged Advanced NSCLC, Including Those With Prior Crizotinib Treatment
Non–small cell lung cancer (NSCLC) harboring ALK rearrangement is sensitive to the ALK inhibitor crizotinib (Xalkori), but resistance ultimately occurs. In a phase I study reported in The New England Journal of Medicine, Shaw et al found that the more-potent ALK inhibitor ceritinib was...
Metastatic Neuroblastoma Confined to Distant Lymph Nodes Associated With Better Survival Compared With Other Stage IV Disease
The pattern of metastatic spread is not incorporated into current risk-stratification systems for neuroblastoma. In a retrospective study reported in the Journal of Clinical Oncology, Morgenstern et al found that patients with neuroblastoma with metastatic disease limited to distant lymph nodes...
Long-Term Benefit With Dasatinib After Imatinib Failure in Chronic-Phase CML
Patients with chronic myeloid leukemia (CML) in the chronic phase who are resistant or intolerant to imatinib (Gleevec) can experience long-term benefit with dasatinib (Sprycel), according to results of a randomized phase III study. The CA180-034 study also found that early molecular and...
Tumor Size, Location, and Mitotic Rate, but Not Genotype, Associated With Recurrence-Free Survival in Trial of Adjuvant Imatinib vs Placebo in GIST
The ACOSOG Z9001 (Alliance) study showed that 1 year of adjuvant imatinib (Gleevec) prolonged recurrence-free survival after resection of primary gastrointestinal stromal tumors (GIST). As reported by Corless et al in the Journal of Clinical Oncology, a study evaluating correlation of pathologic...
Electronic Cigarette Usage Associated With Use of Conventional Cigarettes Among Adolescents
“Use of e-cigarettes does not discourage, and may encourage, conventional cigarette use among US adolescents.” This was the conclusion of a cross-sectional analysis of survey data from a representative sample of middle and high school students who completed the National Youth Tobacco...
Erlotinib and Gefitinib Offer Similar Benefit in EGFR-Mutated Non–Small Cell Lung Cancer
A retrospective study has shown that two targeted therapy drugs—erlotinib (Tarceva) and gefitinib (Iressa)—achieved similar outcomes among people with metastatic or recurrent non–small cell lung cancer (NSCLC) harboring an EGFR mutation. These EGFR tyrosine kinase inhibitors have...
Locoregional Progression of Cervical Cancer Follows Reverse Ontogenetic Sequence
In a study reported in The Lancet Oncology, Höckel et al demonstrated that locoregional progression of cervical cancer follows the reverse sequence of establishment of adult tissues in ontogeny. Ontogenetic staging was a better predictor of survival than pathologic staging. Previous work by...
Phase II Study Suggests Benefit of Adding Rituximab to Chlorambucil in First-Line Treatment for Chronic Lymphocytic Leukemia
In a UK phase II study reported in the Journal of Clinical Oncology, Hillmen et al assessed the safety and activity of adding rituximab (Rituxan) to chlorambucil (Leukeran) in first-line treatment of chronic lymphocytic leukemia (CLL). Such a regimen may be an alternative to fludarabine-based...
PARP Inhibitor Veliparib Might Benefit Women With Resistant Gynecologic Cancers and BRCA Mutation
Preliminary research suggests that a targeted oral agent may improve outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies. According to a phase II study presented at the Society of Gynecologic...
Lymphedema Lingers Long After Sentinel Lymph Node Dissection for Early Breast Cancer
Patients with early-stage breast cancer who underwent sentinel lymph node dissection experienced lymphedema more frequently than clinically suspected and with increasing incidence over time, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix...
Long-Term Use of Valproic Acid May Reduce the Risk of Head and Neck Cancer
The antiseizure medication and mood stabilizer valproic acid was associated with a significant reduction in head and neck cancer risk, according to a study recently published in Cancer. The large retrospective cohort study by Kang et al was conducted to evaluate the effects of the drug, a histone...
Long-Term Follow-up Shows Surgery Plus Radiation Offers Mixed Results in Soft-Tissue Sarcoma
Adjuvant radiation following surgery for soft-tissue sarcoma of the extremities did not lead to a survival benefit and seemed to be associated with some degree of long-term limb complications, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix...
Stool Multitarget DNA Test More Sensitive, But Less Specific Than Fecal Immunochemical Test for Colorectal Cancer Screening in Persons at Average Risk
In a study reported in The New England Journal of Medicine, Imperiale et al found that a noninvasive, multitarget stool DNA test—including assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, β-actin, and hemoglobin—was significantly more sensitive but significantly less ...
Risk Factors for Gastrointestinal Adverse Events Studied in Setting of First-Line Bevacizumab/Chemotherapy for Ovarian Cancer
As reported in the Journal of Clinical Oncology, Burger et al assessed risk factors for gastrointestinal adverse events in women with advanced ovarian cancer receiving first-line bevacizumab (Avastin)/chemotherapy with or without bevacizumab maintenance or chemotherapy alone in the phase III...
Women With BRCA1 Mutations May Still Be at Risk for Rare Types of Uterine Cancer After Preventive Salpingo-Oophrectomy
Women with BRCA1 mutations may have an increased risk for developing rare types of aggressive uterine cancer despite having their ovaries and fallopian tubes removed, suggest preliminary findings presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer held ...
Bariatric Surgery May Lower Risk of Uterine Cancer
Women who had bariatric surgery to lose weight had a 70% lower risk of uterine cancer and an even lower risk if they kept the weight off, according to findings presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, held in Tampa, Florida, from March 22 to 25. ...
Audit of NHS Breast Cancer Screening Programme Reveals Significant Variations Between Hospitals in Treatment Outcomes for DCIS
Analysis of data from the UK NHS Breast Screening Programme has shown significant variations in the outcomes of treatment for women with ductal carcinoma in situ (DCIS) between UK hospitals. Dr. Jeremy Thomas, a consultant pathologist at the Western General Hospital, Edinburgh, told the 9th...
ASCO Issues Updated Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
A review by ASCO’s Update Committee of new data from randomized clinical trials has led to a change in recommendations for the use of sentinel lymph node biopsy in patients with early-stage breast cancer. The updated guideline will enable more women with early-stage breast cancer to avoid the ...
Harms Outweigh Benefits for Women Aged 70 and Over in National Breast Cancer Screening Programs
Extending national breast cancer screening programs to women over the age of 70 does not result in a decrease in the number of cancers detected at advanced stages, according to new research from The Netherlands. Instead, researchers told attendees at the 9th European Breast Cancer Conference that...
Obesity and Diabetes Have Adverse Effects on Outcomes Across Breast Tumor Types, Should Be Taken Into Account When Planning Treatment
Both obesity and diabetes have adverse effects on outcomes in breast cancer patients who receive neoadjuvant chemotherapy, according to research presented at the 9th European Breast Cancer Conference. Although a high body mass index (BMI) is known to have a negative impact on cancer development and ...
